<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748059</url>
  </required_header>
  <id_info>
    <org_study_id>030752</org_study_id>
    <secondary_id>HL056693</secondary_id>
    <nct_id>NCT00748059</nct_id>
  </id_info>
  <brief_title>The Pathophysiology of Orthostatic Hypotension</brief_title>
  <official_title>The Pathophysiology of Orthostatic Hypotension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the cause of low blood pressure in selective
      patients who have problems with their involuntary (autonomic) nervous system. These patients
      frequently have had symptoms throughout their life, and their disorder might have a genetic
      basis. The biochemical, physiological and pharmacological procedures in this study should
      help us define the problem and perhaps lead to more effective treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 1996</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hemodynamic changes with standing</measure>
    <time_frame>following test</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood and urine hormones</measure>
    <time_frame>after test</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood volume</measure>
    <time_frame>during supine and/or upright postures</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sympathetic nerve activity</measure>
    <time_frame>during stimulation of sympathetic nervous system</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quantitative sweat testing</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye function</measure>
    <time_frame>once</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep efficiency</measure>
    <time_frame>once</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic rate</measure>
    <time_frame>once</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain response</measure>
    <time_frame>once</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses on questionnaires and computer tasks designed to assess brain function</measure>
    <time_frame>once</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Autonomic Nervous System Diseases</condition>
  <condition>Orthostatic Hypotension</condition>
  <condition>Dopamine Beta-Hydroxylase Deficiency</condition>
  <condition>Orthostatic Intolerance</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Orthostatic Hypotension</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standing or upright tilt</intervention_name>
    <description>stand upright or tilt table test</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microneurography</intervention_name>
    <description>Recording from sympathetic nerve</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>QSweat</intervention_name>
    <description>quantitative sweat testing</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>neck cuff stimulation</intervention_name>
    <description>Blood pressure receptors in the neck arteries may be stimulated by applying suction through a collar around the neck.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine</intervention_name>
    <description>IV Pharmacological Testing
phenylephrine 12.5 - 400 ug, isoproterenol 0.1 - 0.4 ug or higher until desired effect, nitroprusside 0.1 - 1.6 ug/kg, propranolol 1.1 mg/min, edrophonium maximum of 10 mg, atropine .01 mg/kg, tyramine 250-4000 ug or higher until desired effect</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clonidine,yohimbine,metoclopramide,alpha-methyldopa</intervention_name>
    <description>Oral Pharmacological Testing
clonidine 0.1-0.3 mg, yohimbine 5-10 mg, metoclopramide 10 mg, alpha-methyldopa 62.5 mg, placebo</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>BodPod</intervention_name>
    <description>Determination of body composition</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Eye exam</intervention_name>
    <description>Examination of pressure in the eye and eyelid fatiguability. The following eyedrops might be used:
0.5% proparacaine (Alcaine, Allergan, Inc)
Fluress (0.4% benoxinate hydrochloride, fluorescein sodium, Akorn, Inc)
0.5%, 1% tropicamide (Mydriacyl, Alcon)
Over-the-counter preservative-free artificial tears
0.25%, 2.5% and 10% phenylephrine (Bausch and Lomb)
1% cyclopentolate hydrochloride (Alcon)</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sleep study</intervention_name>
    <description>Recording of sleep pattern overnight</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pain response testing</intervention_name>
    <description>Subjects will rate the quality and intensity of 2 pain tasks.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Metabolic chamber</intervention_name>
    <description>Determination of metabolic rate via 24hr stay in whole-room indirect calorimeter</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Brain function studies</intervention_name>
    <description>Questionnaires and computer tasks, an EEG and an MRI may be used to assess brain function.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bicycle Exercise Test</intervention_name>
    <description>Blood pressure and heart rate may be monitored while exercising on a stationary bicycle.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe orthostatic hypotension and other autonomic symptoms but do not meet criteria
             for standard diagnosis

          -  non-smokers

          -  drug-free

          -  able to give informed consent

          -  free of pulmonary, renal, hematopoietic, hepatic and cardiac disease

        Exclusion Criteria:

          -  medications affecting the autonomic nervous system

          -  any chronic illness

          -  anemia (Hct&lt;30)

          -  women of childbearing age who are pregnant or nursing

          -  smokers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily M Garland, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mc.vanderbilt.edu/root/vumc.php?site=adc</url>
    <description>Autonomic Dysfunction Center Website</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2008</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Emily M. Garland</investigator_full_name>
    <investigator_title>Research Associate Professor</investigator_title>
  </responsible_party>
  <keyword>autonomic nervous system diseases</keyword>
  <keyword>blood pressure</keyword>
  <keyword>congenital</keyword>
  <keyword>orthostasis</keyword>
  <keyword>catecholamines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Orthostatic Intolerance</mesh_term>
    <mesh_term>Autonomic Nervous System Diseases</mesh_term>
    <mesh_term>Primary Dysautonomias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Nitroprusside</mesh_term>
    <mesh_term>Methyldopa</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Yohimbine</mesh_term>
    <mesh_term>Isoproterenol</mesh_term>
    <mesh_term>Tyramine</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Edrophonium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

